When I woke up this morning, I did my regular morning routine… Brewed some coffee and while I was waiting I washed down a few Pills with a glass of water. These Pills?
A Multi-Vitamin and an Omega 3 Supplement.
According to a new report Published May 27, 2015 by Allied Market Research the global fish oil ingredient market would reach $2.63 billion by 2020, while an earlier report by Packaged Facts projected the global fish oil retail market to grow to over $30 Billion. Blue Ocean NutraSciences plans to tap into this market with a unique patented product to which they hold the exclusive rights.
BlueOcean NutraSciences Inc. is a Canadian listed public company (TSXV:BOC) that is focused on developing sustainable, specialty nutraceutical oil products targeted at the rapidly growing Natural Astaxanthin, Omega-3 and Algal oil health and wellness markets.
On May 27th we got the opportunity to speak with Dil Vashi of BlueOcean NutraSciences. After learning about the company and asking a few questions, we decided to share the BlueOcean story with our readers.
Joe: “What has been the biggest challenge or hurdle you have been faced with?”
Dil Vashi:
The biggest challenge we continually face is time and money, as most pre-revenue companies face. While we have formed partnerships with a number of strong companies including our Northern shrimp feedstock JV partner, our extended release tablets JV partner, shrimp oil extraction partner, and universities that we work with, the technical resources that BlueOcean needs in-house is lacking. For example, when we do extraction trials or extended release tableting trials, we then have to send the sample off to a lab for analysis then wait for the results back, and only then can we make the next move in the development track. If we had the capital we could invest in our own labs and people to do in-house analysis that would save us a lot of time, however the costs of such a lab and human resources is very expensive so we have to outsource such functions and the price is time. But alas, we are now at a point where we have developed our shrimp oil product and close to completing the tablets development, and once we go revenue positive and have some cash in the bank we will be able to make such investments in an in-house lab.
In October 2014 BlueOcean announced the signing of an exclusive world-wide, royalty-bearing, non-transferable, License Agreement under Neptune’s composition and extraction patents on the production and sale of marine derived oil products containing phospholipids. The License allows BlueOcean and its shrimp joint venture affiliate to produce and sell shrimp oil products extracted from three species of North Atlantic cold water shrimp (Pandalus borealis, Pandalus montagui, and Pandalus jordani) and seven species of Indo-Pacific Ocean shrimp (Penaeus monodon, Penaeus indicus/Fenneropenaeus indicus, Penaeus vannamei, Metapenaeus dobsoni, Parapenaeopsis stylifera, Metapenaeus monoceros and Metapenaeus affinis) in the nutraceutical, dietary ingredients, natural health products, functional food and food supplements markets
Joe: “Can you explain your relationship with Neptune?”
Dil Vashi:
BlueOcean has been granted the exclusive license from Neptune Technologies to sell bulk shrimp oil in North America and Australia as shrimp oil contains the Neptune patented phospholipid bound omega-3s, similar to krill. In addition, BlueOcean has also filed numerous patents of it’s own. Therefore, with the Neptune phospholipid license exclusively for shrimp oils, BlueOcean has created a substantial barrier to entry for shrimp oil in these markets. Neptune is also a shareholder in BlueOcean as the initial license fee down payment was paid by shares in BOC.
Joe: “What milestones should investors look out for in the next couple quarters?”
Our biggest milestone in the next couple of months is completing supply agreements and receiving purchase orders for our bulk shrimp oils. We also expect to complete our extended release tablets formulations and expect to complete supply agreements and purchase orders for our shrimp oil and fish oil tablets. Finally, we will be launching our own brand of direct to consumer shrimp oil gel caps and tablets as well as fish oil tablets via an online retail platform.
As Dil mentioned, BlueOcean’s future plans of creating an in-house Lab for product analysis should alleviate one of their biggest challenges. With the addition of an online retail platform, supply agreements and purchase orders we expect to see positive revenues from BlueOcean NutraSciences in 2015.
Our thoughts on investing in Blue Ocean are similar to CEO Gavin Bogle’s response to a question asked by Peter Epstein of Epstein Research:
Peter: Are there compelling reasons for prospective investors to buy BlueOcean stock sooner rather than later?
I think the most compelling reason to buy our stock now is that we are currently a pre-revenue company but expect significant revenues in 2015 and expect our share price to react accordingly.
Read more about BlueOcean NutraSciences from Epstein Research’s recent article:
http://epsteinresearch.com/2015/05/21/blueocean-nutrasciences-looking-for-a-hit-in-the-omega-biz-with-shrimp-oil/
